Prestige Consumer Healthcare Stock Forecast, Price & News

Prestige Consumer Healthcare (NYSE:PBH) Frequently Asked Questions

Is Prestige Consumer Healthcare a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Prestige Consumer Healthcare stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PBH, but not buy additional shares or sell existing shares.
View analyst ratings for Prestige Consumer Healthcare or view top-rated stocks.

How has Prestige Consumer Healthcare's stock price been impacted by COVID-19?

Prestige Consumer Healthcare's stock was trading at $35.91 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PBH shares have increased by 54.7% and is now trading at $55.54.
View which stocks have been most impacted by COVID-19.

When is Prestige Consumer Healthcare's next earnings date?

Prestige Consumer Healthcare is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for Prestige Consumer Healthcare.

How were Prestige Consumer Healthcare's earnings last quarter?

Prestige Consumer Healthcare Inc. (NYSE:PBH) announced its earnings results on Thursday, November, 4th. The company reported $1.02 EPS for the quarter, topping the consensus estimate of $0.99 by $0.03. The business had revenue of $276.23 million for the quarter, compared to analyst estimates of $261.23 million. Prestige Consumer Healthcare had a trailing twelve-month return on equity of 13.71% and a net margin of 17.56%. The business's revenue for the quarter was up 16.3% compared to the same quarter last year. During the same period last year, the company earned $0.78 EPS.
View Prestige Consumer Healthcare's earnings history.

What guidance has Prestige Consumer Healthcare issued on next quarter's earnings?

Prestige Consumer Healthcare issued an update on its FY 2022 earnings guidance on Thursday, November, 18th. The company provided EPS guidance of $3.930-$3.980 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.980. The company issued revenue guidance of $1.05 billion-$1.06 billion, compared to the consensus revenue estimate of $1.05 billion.

What price target have analysts set for PBH?

3 analysts have issued twelve-month price objectives for Prestige Consumer Healthcare's shares. Their forecasts range from $63.00 to $126.00. On average, they expect Prestige Consumer Healthcare's stock price to reach $104.67 in the next twelve months. This suggests a possible upside of 88.5% from the stock's current price.
View analysts' price targets for Prestige Consumer Healthcare or view top-rated stocks among Wall Street analysts.

Who are Prestige Consumer Healthcare's key executives?

Prestige Consumer Healthcare's management team includes the following people:

• Ronald M. Lombardi, Chairman, President & Chief Executive Officer
• Jeff Zerillo, Senior Vice President-Operations
• Christine Sacco, Chief Financial Officer
• William C. P'Pool, Secretary, Senior Vice President & General Counsel
• Adel Mekhail, Executive Vice President-Marketing & Sales

What is Ronald M. Lombardi's approval rating as Prestige Consumer Healthcare's CEO?

8 employees have rated Prestige Consumer Healthcare CEO Ronald M. Lombardi on Glassdoor.com. Ronald M. Lombardi has an approval rating of 61% among Prestige Consumer Healthcare's employees. This puts Ronald M. Lombardi in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Prestige Consumer Healthcare's key competitors?

Some companies that are related to Prestige Consumer Healthcare include Estée Lauder Companies (EL), Herbalife Nutrition (HLF), Inter Parfums (IPAR), Medifast (MED), Nu Skin Enterprises (NUS), USANA Health Sciences (USNA), Revlon (REV), Veru (VERU) and Nature's Sunshine Products (NATR).
View all of PBH's competitors.

What other stocks do shareholders of Prestige Consumer Healthcare own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Pfizer (PFE), AbbVie (ABBV), Gilead Sciences (GILD), AT&T (T), Intel (INTC), ONEOK (OKE), Wells Fargo & Company (WFC), International Business Machines (IBM), Micron Technology (MU) and Teva Pharmaceutical Industries (TEVA).

What is Prestige Consumer Healthcare's stock symbol?

Prestige Consumer Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBH."

Who are Prestige Consumer Healthcare's major shareholders?

Prestige Consumer Healthcare's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (15.98%), Dimensional Fund Advisors LP (6.86%), Macquarie Group Ltd. (3.48%), Turtle Creek Asset Management Inc. (3.20%), Massachusetts Financial Services Co. MA (2.68%) and LSV Asset Management (2.20%). Company insiders that own Prestige Consumer Healthcare stock include Mary Beth Fritz and Ronald M Lombardi.
View institutional ownership trends for Prestige Consumer Healthcare.

Which major investors are selling Prestige Consumer Healthcare stock?

PBH stock was sold by a variety of institutional investors in the last quarter, including Turtle Creek Asset Management Inc., Goldman Sachs Group Inc., BlackRock Inc., Massachusetts Financial Services Co. MA, Eagle Asset Management Inc., Invesco Ltd., Russell Investments Group Ltd., and Royal Bank of Canada. Company insiders that have sold Prestige Consumer Healthcare company stock in the last year include Mary Beth Fritz, and Ronald M Lombardi.
View insider buying and selling activity for Prestige Consumer Healthcare or view top insider-selling stocks.

Which major investors are buying Prestige Consumer Healthcare stock?

PBH stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Foundry Partners LLC, Robeco Institutional Asset Management B.V., Nordea Investment Management AB, Alliancebernstein L.P., LSV Asset Management, Two Sigma Investments LP, and Jennison Associates LLC.
View insider buying and selling activity for Prestige Consumer Healthcare or or view top insider-buying stocks.

How do I buy shares of Prestige Consumer Healthcare?

Shares of PBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Prestige Consumer Healthcare's stock price today?

One share of PBH stock can currently be purchased for approximately $55.54.

How much money does Prestige Consumer Healthcare make?

Prestige Consumer Healthcare has a market capitalization of $2.78 billion and generates $943.36 million in revenue each year. The company earns $164.68 million in net income (profit) each year or $3.54 on an earnings per share basis.

How many employees does Prestige Consumer Healthcare have?

Prestige Consumer Healthcare employs 505 workers across the globe.

What is Prestige Consumer Healthcare's official website?

The official website for Prestige Consumer Healthcare is www.prestigebrands.com.

Where are Prestige Consumer Healthcare's headquarters?

Prestige Consumer Healthcare is headquartered at 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591.

How can I contact Prestige Consumer Healthcare?

Prestige Consumer Healthcare's mailing address is 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591. The company can be reached via phone at (914) 524-6800, via email at [email protected], or via fax at 302-674-5266.